Slot, RER;
Verfaillie, SCJ;
Overbeek, JM;
Timmers, T;
Wesselman, LMP;
Teunissen, CE;
Dols, A;
... Van der Flier, WM; + view all
(2018)
Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results.
Alzheimer's Research & Therapy
, 10
, Article 76. 10.1186/s13195-018-0390-y.
Preview |
Text
Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results.pdf - Published Version Download (1MB) | Preview |
Abstract
BACKGROUND: We aimed to describe the Subjective Cognitive Impairment Cohort (SCIENCe) study design, to crosssectionally describe participant characteristics, and to evaluate the SCD-plus criteria. METHODS: The SCIENCe is a prospective cohort study of subjective cognitive decline (SCD) patients. Participants undergo extensive assessment, including cerebrospinal fluid collection and optional amyloid positron emission tomography scan, with annual follow-up. The primary outcome measure is clinical progression. RESULTS: Cross-sectional evaluation of the first 151 participants (age 64 ± 8, 44% female, Mini-Mental State Examination 29 ± 2) showed that 28 (25%) had preclinical Alzheimer’s disease (AD) (amyloid status available n = 114 (75%)), 58 (38%) had subthreshold psychiatry, and 65 (43%) had neither. More severe subjective complaints were associated with worse objective performance. The SCD-plus criteria age ≥ 60 (OR 7.7 (95% CI 1.7–38.9)) and apolipoprotein E (genotype) e4 (OR 4.8 (95% CI 1.6–15.0)) were associated with preclinical AD. CONCLUSIONS: The SCIENCe study confirms that SCD is a heterogeneous group, with preclinical AD and subthreshold psychiatric features. We found a number of SCD-plus criteria to be associated with preclinical AD. Further inclusion and follow-up will address important questions related to SCD.
| Type: | Article |
|---|---|
| Title: | Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1186/s13195-018-0390-y |
| Publisher version: | http://dx.doi.org/10.1186/s13195-018-0390-y |
| Language: | English |
| Additional information: | © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Clinical Neurology, Neurosciences, Neurosciences & Neurology, Subjective cognitive decline, Preclinical Alzheimer's disease, Subthreshold psychiatry, SCD-plus criteria, Study design, PRECLINICAL ALZHEIMERS-DISEASE, CEREBROSPINAL-FLUID BIOMARKERS, DWELLING OLDER-ADULTS, MEMORY COMPLAINTS, AMYLOID-BETA, CLINICAL PROGRESSION, DEPRESSIVE SYMPTOMS, HEALTH-PROBLEMS, FOLLOW-UP, DECLINE |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Brain Repair and Rehabilitation |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10054807 |
Archive Staff Only
 |
View Item |
